Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for its product, Wengjing Decoction Granules, which is derived from a historical prescription and is aimed at treating specific gynecological conditions [1] Group 1: Product Information - Wengjing Decoction Granules is based on a prescription from the Song Dynasty and is included in the first batch of the National Administration of Traditional Chinese Medicine's list of classic ancient formulas [1] - The formulation consists of nine ingredients, including cinnamon, wine-soaked angelica, chuanxiong, vinegar-curcuma, peony root, and wine-soaked achyranthes [1] - The product is indicated for conditions such as menstrual irregularities and abdominal pain due to blood deficiency and stagnation [1] Group 2: Financial Investment - The company has invested a total of 10.7155 million RMB in the research and development of this product to date [1]

Meeting Overview - The fifth extraordinary general meeting of shareholders was held on October 10, 2025, at the company's conference room [2] - The meeting was conducted in accordance with the Company Law and the company's articles of association, combining on-site and online voting [2][3] Attendance and Voting - All 15 current directors and 5 supervisors attended the meeting, along with the board secretary [3] - The meeting's agenda included a non-cumulative voting proposal regarding the use of idle funds to purchase bank wealth management products, which was approved [3][4] Legal Verification - The meeting was witnessed by lawyers from Inner Mongolia Jianzhong Law Firm, who confirmed that the meeting's procedures complied with relevant laws and regulations [4] - The legal opinion stated that the qualifications of attendees were valid and the voting procedures and results were legitimate [4]

证券代码：600535 证券简称：天士力 编号：临2025-067号 天士力医药集团股份有限公司 2025年第五次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 10 月 10 日 (二) 股东大会召开的地点：天士力医药集团股份有限公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 1,457 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 659,271,256 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 46.4520 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董事 会召集，根据《公司章程》有关规定，由董事长周辉女士现场主持本次会议。会议 的召 ...

本所同意贵公司将本法律意见书作为贵公司本次股东大会公告材料，随其他 文件一同公开披露，并对贵公司引用的本法律意见承担相应的法律责任。 本所经办律师根据《证券法》、《股东大会规则》和《章程》的要求，按照 内蒙古建中律师事务所 关于天士力医药集团股份有限公司 2025 年第五次临时股东大会的法律意见书 2025 内建中券意字第 24 号 致：天士力医药集团股份有限公司 内蒙古建中律师事务所（以下称"本所"）受天士力医药集团股份有限公司 （以下称"贵公司"或"公司"）的委托，指派本所执业律师郭瑞鹏、张辛羽（以 下称"本所经办律师"）出席了贵公司 2025 年第五次临时股东大会（以下称"本 次股东大会"），并根据《中华人民共和国证券法》（以下称"《证券法》"）、 《中华人民共和国公司法》（以下称"《公司法》"）和中国证监会《上市公司 股东大会规则》（以下称"《股东大会规则》"）等法律、法规和规范性文件以 及《天士力医药集团股份有限公司章程》（以下称"《章程》"）的规定，就本 次股东大会的召集、召开程序、出席会议人员资格以及表决程序和表决结果的合 法有效性出具本法律意见书。 为出具本法律意见书，本所经办律师已对本次股东 ...

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. announced a cash dividend distribution of 0.21 CNY per share for the first half of 2025, approved at the fourth extraordinary general meeting of shareholders on September 2, 2025 [2][4]. Summary by Sections Dividend Distribution - The cash dividend distribution is set at 0.21 CNY per share, amounting to a total cash distribution of approximately 313.73 million CNY based on a total share capital of 1,493,950,005 shares [2][4]. Distribution Objects - The distribution will be made to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the day before the equity registration date [3]. Implementation Method - For shareholders with unrestricted circulating shares, dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited. Shareholders who have completed designated transactions can collect their cash dividends at their designated securities business department on the dividend distribution date [5]. Special Distribution Cases - Certain entities, such as China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Tasly Biopharmaceutical Industry Group Co., Ltd., and Tianjin New Technology Industry Park Yongsheng Construction Co., Ltd., will receive their cash dividends directly from the company [6]. Taxation Details - For individual shareholders holding shares for over one year, the cash dividend of 0.21 CNY per share is exempt from individual income tax. For those holding shares for one year or less, the tax will be calculated upon the transfer of shares [9]. - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied, resulting in a net cash dividend of 0.189 CNY per share [10]. - For Hong Kong investors, a similar 10% withholding tax applies, leading to a net cash dividend of 0.189 CNY per share [10]. - Other corporate shareholders will not have tax withheld by the company and must determine their tax obligations independently, receiving a cash dividend of 0.21 CNY per share [10].

Core Points - Tianjin Tasly Pharmaceutical announced its profit distribution plan for the first half of 2025, which includes a cash dividend of 0.21 yuan per share (tax included) for A-shares [2] - The record date for the dividend is set for October 16, 2025, while the ex-dividend date and the date of cash dividend distribution are both scheduled for October 17, 2025 [2]

证券代码：600535 证券简称：天士力 编号：临2025-066号 天士力医药集团股份有限公司2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.21元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/10/16 | － | 2025/10/17 | 2025/10/17 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 9 月 2 日的2025年第四次临时股东大会审议通 过。 二、分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公 司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本1,493,950,0 ...

脑卒中，是指由于脑部血管突然破裂或血管阻塞而引起脑组织损伤的一组疾病。由于高死亡率和高致残 率的特点，脑卒中长期以来都被视作"人类健康的头号杀手"。据统计，我国每年约有440万脑卒中新发 病例，其中缺血性脑卒中约占80%，给家庭和社会带来了沉重负担。 在临床治疗上，静脉溶栓被确立为急性缺血性脑卒中（AIS）的标准治疗手段。然而，目前我国整体静 脉溶栓率仅约7.6%，与发达国家存在差距。这背后，一方面是患者就诊时间与治疗窗口错配，另一方 面也与溶栓药物治疗过程伴发的高出血风险，导致了临床用药的顾虑。 近日，天士力宣布，其自主研发的生物创新药注射用重组人尿激酶原（普佑克）获批新适应症，用于急 性缺血性脑卒中的溶栓治疗。国产创新药普佑克的出现，不仅有望缓解我国AIS患者治疗中的痛点问 题，也标志着天士力从传统中药企业向创新药领军企业转型迈出了关键一步。 卒中防治的时代命题：如何推动药物走下基层？ 在卒中防治中，救治率低始终是绕不开的临床痛点。 "发病后4.5小时内"是静脉溶栓的黄金时间窗。然而，CHINA QUEST研究显示，我国有67%-75%的急性 缺血性卒中患者因延迟就诊或发病时间不明而错过溶栓机会。公众对卒 ...

Core Points - The 2025 Hong Kong International Traditional Chinese Medicine Conference opened on September 25, focusing on the theme "Revitalizing Traditional Medicine for the Benefit of Human Health" [1] - The conference attracted over 130 well-known enterprises and institutions from countries involved in the Belt and Road Initiative, showcasing the global interest in traditional Chinese medicine [1] Company Highlights - Five listed Chinese medicine companies, including China Resources Sanjiu, Tianshi, and Kunming Pharmaceutical Group, collaborated with Zijing Culture to launch the "Traditional Chinese Medicine Culture Co-Link Initiative" [1] - The companies presented the "Traditional Chinese Medicine Culture" blue book and shared achievements in industry chain construction, highlighting their commitment to the development of traditional Chinese medicine [1] Industry Insights - The conference provided a platform for the Chinese medicine industry to gain domestic and international recognition for its achievements in industry chain construction [1] - The initiative aims to promote traditional Chinese medicine from being a "Chinese treasure" to a "global shared resource," contributing Chinese wisdom and solutions to global health [1]

Group 1 - The core viewpoint of the article highlights the target price increases for several listed companies, with notable gains for Dongcai Technology, Seres, and Gree Electric, showing target price increases of 51.97%, 37.62%, and 36.96% respectively [1][3] - On September 25, a total of 12 target price adjustments were made by brokerages, with the highest target price set at 32.43 yuan for Dongcai Technology [1][3] - A total of 35 listed companies received brokerage recommendations on September 25, including Sanyuan Shares, Anhui Weaving High-tech, and Yixin Pharmacy [1][3] Group 2 - On the same date, two companies had their ratings upgraded, with Renfu Pharmaceutical's rating raised from "Hold" to "Buy" by Shouchuang Securities, and Sanhuan Group's rating upgraded from "Hold" to "Buy" by Huazheng Securities [4][6] - A total of 10 companies received initial coverage from brokerages, with Frontier Biotech receiving a "Buy" rating from Kaiyuan Securities and Jiete Biotech also receiving a "Buy" rating from Xinda Securities [4][7] - Other companies receiving initial coverage include Bowei Alloy with a rating of "Hold" and Leisai Intelligent with a "Buy" rating, indicating a diverse range of sectors being covered [4][7]